Trials / Withdrawn
WithdrawnNCT02410590
Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)
Randomized, Parallel Group, Controlled Trial to Compare Two Different "NMB + Reversal" Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to compare the preference between two strategies of neuromuscular blocking (NMB) / reversal in adult obese patients undergoing laparoscopic abdominal surgery: Rocuronium + Sugammadex versus Succinylcholine + Cisatracurium + Neostigmine/Atropine. This will be done evaluating the average verbal numerical scale (VNS) scores obtained from surgeons blinded to the drugs administered. The primary hypothesis is that the strategy "Rocuronium + Sugammadex" provides a better surgical visual field in obese participants undergoing laparoscopic abdominal surgery than the strategy "Succinylcholine + Cisatracurium + Neostigmine/Atropine" as measured by VNS scores.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocuronium | |
| DRUG | Sugammadex | |
| DRUG | Cisatracurium | |
| DRUG | Neostigmine/Atropine | |
| DRUG | Succinylcholine |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2015-04-07
- Last updated
- 2015-07-13
Source: ClinicalTrials.gov record NCT02410590. Inclusion in this directory is not an endorsement.